Alerts
Modified Hours for Thanksgiving

In recognition of the upcoming Thanksgiving holiday, some of our offices will have modified hours over the long weekend. Check here for modified hours.

Skip Navigation

A Phase II, Open-Label, Multicenter Study of Arlocabtagene Autoleucel BMS-986393, a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma. QUINTESSENTIAL

Brief Summary

Type:
Multiple Myeloma

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT06297226

Study #:
STUDY00160251

Start Date:
Jul 08, 2024

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT06297226

View Complete Trial Details & Eligibility at ClinicalTrials.gov